Valuation: Axogen, Inc.

Market Cap 2.16B 1.89B 1.74B 1.61B 3.05B 206B 3.1B 20.82B 8.17B 101B 8.1B 7.93B 349B P/E 2026 *
-104x
P/E 2027 * 263x
Enterprise Value 2.16B 1.89B 1.74B 1.61B 3.05B 206B 3.1B 20.82B 8.17B 101B 8.1B 7.93B 349B EV / Sales 2026 *
7.97x
EV / Sales 2027 * 6.78x
Free-Float
96.5%
Yield 2026 *
-
Yield 2027 * -
1 day-6.97%
1 week-11.57%
Current month-12.15%
1 month-1.84%
3 months+26.97%
6 months+21.10%
Current year+23.98%
1 week 39.55
Extreme 39.55
46.95
1 month 39.55
Extreme 39.55
46.95
Current year 27.54
Extreme 27.54
46.95
1 year 11.25
Extreme 11.25
46.95
3 years 3.45
Extreme 3.45
46.95
5 years 3.45
Extreme 3.45
46.95
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 2024-08-08
Director of Finance/CFO 42 2025-05-11
Chief Tech/Sci/R&D Officer - 2024-01-03
Director TitleAgeSince
Chairman 70 2024-08-08
Director/Board Member 65 2016-08-31
Director/Board Member 68 2021-07-18
Date Insider Type Main position Quantity % Market Cap.
06-23Free

Director

4,392 0.0083%
06-23Free

Director

4,392 0.0083%
06-23Free

Director

4,392 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
-6.97%-11.57%+236.76%+380.81% 2.16B
+0.45%+0.69%+22.36%+1.97% 196B
-1.16%-4.51%-22.67%+19.55% 144B
+1.57%+0.57%-3.14%-15.11% 141B
-0.49%-0.82%-56.89%-15.05% 66.54B
+0.96%-2.29%+17.02%+0.62% 53.09B
+0.61%-1.09%-27.71%-30.42% 44.12B
+0.52%+2.75%+8.15%+13.46% 37.93B
-0.19%-0.75%+6.55%+42.23% 36.96B
-2.20%-2.75%-21.00%-5.88% 29.41B
Average -0.69%-2.06%+15.94%+39.22% 75.1B
Weighted average by Cap. +0.16%-1.05%-3.98%+1.98%

Financials

2026 *2027 *
Net sales 271M 237M 219M 202M 383M 25.83B 390M 2.61B 1.03B 12.73B 1.02B 995M 43.79B 318M 279M 257M 238M 451M 30.37B 458M 3.07B 1.21B 14.96B 1.2B 1.17B 51.48B
Net income -21.17M -18.55M -17.1M -15.8M -29.96M -2.02B -30.46M -204M -80.13M -995M -79.48M -77.75M -3.42B 8.06M 7.06M 6.51M 6.01M 11.4M 768M 11.59M 77.74M 30.49M 378M 30.25M 29.59M 1.3B
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
26-07-10 US$40.58 -6.97% 2,139,742
26-07-09 US$43.62 +2.04% 1,714,846
26-07-08 US$42.75 -4.08% 1,052,340
26-07-07 US$44.57 -3.05% 1,291,264
26-07-06 US$45.97 +0.17% 1,631,968
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
40.58USD
Average target price
50.78USD
Spread / Average Target
+25.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock